The role of cancer-associated fibroblasts, solid stress and other microenvironmental factors in tumor progression and therapy resistance

Gvantsa Kharaishvili1, Dana Simkova1, Katerina Bouchalova2, Mariam Gachechiladze1, Nato Narsia3 and Jan Bouchal1*

Abstract
Tumors are not merely masses of neoplastic cells but complex tissues composed of cellular and noncellular elements. This review provides recent data on the main components of a dynamic system, such as carcinoma associated fibroblasts that change the extracellular matrix (ECM) topology, induce stemness and promote metastasis-initiating cells. Altered production and characteristics of collagen, hyaluronan and other ECM proteins induce increased matrix stiffness. Stiffness along with tumor growth-induced solid stress and increased interstitial fluid pressure contribute to tumor progression and therapy resistance. Second, the role of immune cells, cytokines and chemokines is outlined. We discuss other noncellular characteristics of the tumor microenvironment such as hypoxia and extracellular pH in relation to neoangiogenesis. Overall, full understanding of the events driving the interactions between tumor cells and their environment is of crucial importance in overcoming treatment resistance and improving patient outcome.

Keywords: Tumor microenvironment, Cancer associated fibroblasts, Solid stress, Interstitial fluid pressure, Therapy resistance

Background
Tumor progression is partly a result of evolving cross-talk between different cell types within the tumor and its surrounding supportive tissue or tumor stroma [1]. Invasive tumor cells interact with the microenvironment and remodel it into a milieu supportive of tumor growth and tumor progression. The altered environment is recognizable under light microscope as desmo-plasia and this is used for assessing invasion [2]. The importance of the microenvironment in tumor progression is shown using model systems. It has been shown on animal xenografts that injection of purified malignant epithelial cells results in the formation of histologically complex tumors, with 80% of the cells being stromal [3]. Further, injection of non-transformed mammary epithelial cells into irradiated mammary stromal fat pads, resulted in increased tumor growth compared to those injected into contralateral, non-irradiated mammary fat pads. Irradiated stromal cells altered the microenvironment and this resulted in tumor promotion [4]. Genetic alterations that initiate carcinoma, occur in the epithelium but events that promote tumor progression involve the stroma. In some cases, the trigger for neoplastic progression is speculated to come from signals within the stromal microenvironment [5]. Cancer cells release stroma-modulating growth factors such as fibroblast growth factor, members of the VEGF family, PDGF, EGFR ligands, interleukins, colony-stimulating factors, transforming growth factor β and many others [6]. These factors act in a paracrine manner, disrupt normal tissue homeostasis, resulting in stromal reactions such as angiogenesis and the inflammatory response [7,8].

Fibroblasts in tumor progression and therapy resistance
Carcinoma associated fibroblasts (CAF) are believed to influence tumor behavior and outcome and thus knowledge...
of their biology is of importance to an overall understanding of cancer. CAFs are large, spindle-shaped mesenchymal cells that share characteristics with smooth muscle cells and fibroblasts [6]. They constitute a significant component of the stroma and represent the cells responsible for the change of extracellular matrix composition into one with increased amounts of collagens (desmoplastic response) [3]. Currently, no precise definition of CAFs exists because of the different cellular origin and markers expressed: CAFs are likely to derive from resident fibroblasts and narrow-derived mesenchymal precursor cells, whereas their generation through epithelial-mesenchymal transition (EMT) of tumor cells is more controversial [6,9,10]. CAFs are not only phenotypically but also functionally distinct from their normal counterparts and are identified immunocyto-/histochemically based on different markers such as a-smooth muscle actin (a-SMA), vimentin, desmin, fibroblast specific protein −1, PDGF α and β, and fibroblast activation protein or their combinations; CAFs generally lose caveolin 1, PTEN, p21, or have mutated TP53 [11,12]. Some of these differences are reversible, whereas others persist when the fibroblasts are removed from the vicinity of the carcinoma cells. Their gene expression differences are due to epigenetic and genetic alterations [13,14] and relate to the stage of their differentiation [15]. The evidence above shows that CAFs, like tumor cells, are heterogenous, not only between different but also within the same type of cancer.

CAFs promote tumor progression in several ways such as secretion of multiple factors and MMPs, inducing stemness, EMT, epigenetic changes, etc. [11,16]. Recent breast cancer gene expression profiles of the stromal compartment, have revealed significantly different gene sets than normal mammmary stroma, with increased cytokines, ECM molecules and proteases [17,18]. They alter the three dimensional ECM scaffold and support tumor cells that eventually metastasize and activate immune cells to enhance the ECM-degrading capacity [19]. Secreted ECM components such as tenascin reveal pro-migratory activity [20]. TGF-β induces HGF expression by fibroblasts and also induces the transition of fibroblasts to myofibroblasts by increasing α-SMA and tenasin C expression [21]. Gene expression changes, reported by Rajski et al., [22], which were induced by IGF-I in human breast fibroblasts, contained several soluble factors, such as periostin which is involved in bone metastasis and angiogenesis [23-25], tenasin, which enhances tumor cell proliferation [26], as well as LOXL1, a member of the lysyl oxidase family. LOXL1 like LOXL2, may act in the vicinity of epithelial cells during tissue remodeling and collagen cross-linking. LOXL2 has been reported to be involved in invasiveness [27] and specifically expressed by fibroblasts in tumor tissue [28]. The presence of these factors indicates that the IGF-I activated stroma enhances proliferation and the metastatic potential of the cancer cells. In this sense, periostin and tenasin C also activate developmental pathways for the viability of metastasis-initiating cells in the lungs [29]. In the pulmonary parenchyma, TGF-β3 stimulates myofibroblasts to produce periostin which binds stromal Wnt factors Wnt1 and Wnt3a for presentation to stem-like metastasis-initiating cells [30]. Myofibroblasts and the cancer cells themselves also produce tenasin C which promotes the intracellular functioning of the Wnt and Notch pathways [29]. The Wnt pathway is known to control stem cell maintenance in a variety of tissues [31] and tumors [32,30,33,34]. We previously identified another cancer associated extracellular matrix protein, asporin which may interact with the Wnt pathway [35-38]. Asporin was also identified as one of the most CAF-enriched molecules using gene ontology analysis and further suggested as a possible EMT marker due to colocalization with ZEB1 both in the stroma and epithelium of prostate cancer [39]. In breast and prostate carcinomas, mutations of critical tumor suppressor genes like PTEN and TP53 have been reported to occur in either epithelial or stromal cells in a mutually exclusive fashion [40,41]. Such findings indicate establishment of a vicious circle, in which mutations in the carcinoma drive alterations in the stroma that again promote carcinoma progression [40,41]. According to Dudley et al. [42], breast CAFs possess a nonmutated but functionally deficient form of p53 and TP53 mutation status may be a predictor of CAF-mediated chemoresistance [43]. The role of CAFs in chemo/endocrine and target resistance is well-reviewed in Mao et al. [11] using breast cancer as example. Besides the genetic mechanisms described above, there is also evidence supporting the involvement of epigenetic changes in the cancer stroma as a contributor to cancer progression. These include histone modifications and alterations in the expression of DNA methyltransferases, chromatin modifying factors and microRNAs [11]. Direct contact between stromal and tumor cells allows minor populations of the latter to evade chemotherapy. For example, adhesion of melanoma cells to fibroblast monolayers through N-cadherin activates AKT, which blocks BAD and significantly reduces the cytotoxic effects of the chemotherapy drug, cisplatin [44]. In summary, CAFs play a critical role in determining many aspects of tumor behavior and overall outcome.

Matrix topology, stiffness and solid stress
Cancer initiation and progression are largely dependent on the physical and chemical features of the adjacent environment particularly matrix topology (architecture) and stiffness. These features are determined by the size of biopolymer (proteins, proteoglycans and glycosaminoglycans) fibers and the density of the fiber network [45].
Connective tissue is characterized by different fiber arrangements ranging from loose or random to highly aligned structures. ECM topology can provide important regulation of cell motility through physical cues that geometrically constrain adhesion sites to guide directional migration [46]. Cancer cells display aligning behavior, called contact guidance through which they actively remodel the ECM fibers surrounding a tumor, using contractile force to align the fibers perpendicularly to the tumor [47]. Dense fibrous collagen that is characteristic of breast cancer stroma forms radial patterns extending away from tumors [48]. On the other hand, the reticular orientation of the collagen matrix surrounding mammary glands may anchor and/or restrain cells. Thus, non-linear matrix reduces invasion while linear structure promotes it (reviewed in [46]).

Matrix concentration and post-translational modifications such as glycosylation and cross-linking (e.g. by LOXL1 and LOXL2) affect the mechanical properties, including visco-elasticity or stiffness (reviewed in [49]). Tumors are stiffer than their normal adjacent tissue. For example, healthy mammary gland is highly compliant (elastic modulus $E = \sim 200$ Pa), while the average tumor is over an order of magnitude stiffer ($E = \sim 4,000$ Pa). Both the tumor-surrounding stroma and vasculature exhibit increased stiffness ($E = \sim 800–1,000$ Pa and $\sim 450$ Pa, respectively) [47]. Increased matrix stiffness is also observed in fibrotic lungs, scar tissue and irradiated or aged tissue [50].

ECM topology and stiffness can influence mechanosensing and activate intracellular signaling to promote directional cell migration. Integrin receptors and the physical arrangement of adhesions could trigger orientation of the cytoskeleton, and matrix orientation can also stabilize leading edge protrusions to promote directionally persistent migration in which specific signaling pathways (via vinculin, talin, FAK, p130CAS and filamin A) are involved [45,46]. Cancer cells recognize an increase in ECM stiffness and respond by generating increased traction forces on their surroundings by regulating focal adhesion formation and growth factor signaling. For this purpose, the cell has several options: it can either force the network fibers apart and remodel the shape until it can pass through the pore, or tumor cell degrades the fiber matrix with the help of proteolytic enzymes (reviewed in [45]). This in turn, enhances growth, survival, and invasion of tumor cells by promoting focal adhesion maturation and signaling through actomyosin contractility [51]. Increased tumor tissue stiffness has been linked to tumor progression, direct stem cell differentiation, cell–cell and cell–matrix adhesion, hyaluronan synthesis, and expression of genes that play important roles in invasion and metastasis [52-54].

Another important tumor characteristic is growth-induced solid stress (Figure 1). As tumor cells proliferate they sequentially create new solid material (i.e. cells and matrix components) which pushes against the surrounding tumor microenvironment. In normal tissue, the expansion of the tumor microenvironment is resisted by the enclosing microenvironment. However, cancer cells proliferate uncontrollably, ignoring contact inhibition and their expansion imposes elastic strain on the surrounding tumor microenvironment, storing stress through the deformation of compliant structures and collapsing more fragile structures, such as blood and lymphatic vessels (Figure 1). Interestingly, this solid stress is accumulated within the tumor and maintained even after the tumor is excised [55]. The known contribution of the ECM to solid stress includes both collagen and hyaluronan. Collagen resists tensile stress because it becomes stiffer as it is stretched. This finding is true for both capsular and interstitial collagen because the ECM in tumors is extensively cross-linked. Whereas hyaluronan resists compression, its negatively charged chains repel, owing to electrostatic repulsion and trap water, forming a poorly compressible matrix [55]. The compression of vessels by solid stress creates two potential barriers to drug delivery. First, the collapse of blood vessels hinders access of systemically...
administered drugs. This collapse might explain, in part, the fact that tumors with more ECM might be more resistant to treatment. For instance, pancreatic ductal adenocarcinomas, chondrosarcomas, and chordomas are rich in ECM and refractory to chemotherapy [56-58]. Second, the lack of lymphatic vessel function reduces drainage, leading to uniformly elevated interstitial fluid pressure (please see below). As a result, the transport of therapeutics, like antibodies and nanoparticles, is reduced because the dominant means of transport becomes diffusion which is a very slow process for large particles and macromolecules [59]. In this sense, decreasing solid stress by the inexpensive angiotensin inhibitor, losartan, enhances drug delivery and potentiates chemotherapy by decompressing tumor blood vessels [60].

**Immune cells in tumor microenvironment**

Besides endothelial cells and fibroblasts, the tumor microenvironment also harbors innate and adaptive immune cells. It is a complex and highly dynamic system that should concomitantly work to eradicate a tumor. However, once a system is deformed, immunity becomes a benefit for the tumor and provides a very important cue to its development and progression [61]. The tumor-promoting effect of chronic inflammation has been reported many times [62,63]. However, how tumors promote inflammation and engage inflammatory cells in this process, is still being intensively studied. Macrophage density in the tumor generally negatively correlates with relapse-free and overall survival but localization also seems to be important. The association between TAM (tumor associated macrophage)-density and survival of cancer patients depends on the intratumoral or peritumoral macrophages counted [15]. TAMs promote the metastatic capacity of cancer cells in stromal or perivascular areas, while around the necrosis, in a hypoxic state, they stimulate angiogenesis [64]. A fibroblast secreted protein-1 (FSP1), also called S100A4 and mts1, is secreted by both fibroblasts and cancer cells, and also possibly by macrophages [65], making the environment more favourable to tumor progression by regulating inflammation and angiogenesis and promoting metastasis [66,67]. FSP1 is proangiogenic, possibly mediated either by the activation of plasminogen or through the transcriptional up-regulation of MMP13 [68]. Both of these proteinases play a role in endothelial cell invasion [5].

Immune cells, particularly macrophages and neutrophils are sources of chemokines, growth factors and proteases, as well as DNA-damaging reactive oxygen and nitrogen species. The gene expression profile of macrophages isolated from malignant tumors significantly differs from wound or resting peritoneal macrophage profile, with increased number of proliferation-associated genes [69]. Chemokines are produced not only by activated macrophages but by stromal and even cancer cells themselves. As an example, CXCL12 activates CXCR4 both on the surface of immune cells and on hematopoetic and endothelial precursors. The receptor is also expressed in some cancer cells. Accordingly, CXCL12 has several consequences: i) attraction of immune cells leading to tissue destruction, favoring invasion and metastasis; ii) promotion of growth and survival of cancer cells expressing the CXCR4 receptor; iii) recruitment of precursor cells for vasculogenesis; iv) activation of CXCR4 may also lead to greatly increased production of TNFα which itself exhibits other effects. Inflammatory cytokines, overexpressed by tumor cells recruit monocytes (macrophages), lymphocytes and neutrophils to tumor stroma, where they release VEGF, HGF, metalloproteinase 2 and interleukin 8 which affect endothelial cells and contribute to tumor progression [70]. Up-regulation of tumor-regulated interleukins 6 andβ is also associated with the inflammatory network, tumorigenesis, angiogenesis, and metastasis in breast, prostate, and pancreatic cancers [19]. Breast CAFs initiate and mediate tumorigenesis through a macrophage-recruitment inflammatory signature and is dependent on NF-kB signaling [71]. Recent studies demonstrate that colony stimulating factor (CSF)-1 which represents the main growth and differentiation factor for macrophages is overexpressed in breast, ovarian and prostate cancers [72]. Granulocyte CSF and granulocyte-macrophage CSF also contribute to progression of various cancers through recruitment of monocytes, macrophages and neutrophils into the tumor vicinity (reviewed in [6,73,74]).

**Tumor vasculature, hypoxia and interstitial fluid pressure**

Tumor angiogenesis is an important factor in proliferation, metastasis, and drug sensitivity. Primary tumors without vasculature are small and dormant, while the growth of the tumor mass creates hypoxic conditions in the center of the tumor that induce expression of VEGF and subsequent tumor vascularization [75]. CAFs are also suggested to be an important source for growth factors and cytokines recruiting endothelial cells. These are involved in the establishment of the cancer stem cell niche and metastatic spread of tumor cells into distant organs [76]. Angiogenesis in malignant tumors, as measured by microvessel density correlates with clinicopathological factors or poor survival in many cancer types (reviewed in [77]). Tumor-endothelial cell interactions are mediated mostly by cell surface adhesion molecules (i.e. integrins, cadherins, immunoglobulins and selectins) [78,79]. CD34, CD31, and factor-VIII-related antigen are commonly used as tumor endothelial cell markers and microvessel density is determined by immunodetection of blood vessels with these markers. However, the markers identify not only neovessels but also pre-existing large ones [80]. Nestin has recently received attention as a
marker of newly formed endothelial cells [81,82] and seems promising in the evaluation of neoangiogenesis of different tumors.

Hypoxia is also characteristic of abnormal tumor microenvironment that is intrinsically linked to the formation of neovasculature and is clinically associated with metastasis and poor patient outcome [83,84]. Diffusion-limited hypoxia is a consequence of tumor cells that are distant from the vascular supply. Such cells are exposed to prolonged or chronic hypoxia and tumor cells are viable in such environments for hours or a few days [85,86]. Hypoxia induces oncogene expression, enhances DNA mutation rate, and selects for cells with increased apoptotic thresholds [83,87]. Hypoxia drives tumor progression through increased matrix deposition, cross-linking and remodeling and, enhances collagen turnover and its fibril deposition [88]. Hypoxia-inducible factor (HIF)-1α plays an integral role in the body's response to low oxygen. It is one of the primary genes involved in the homeostatic process which can increase vascularization in hypoxic areas. HIF-1α allows for survival and proliferation of cancer cells due to its angiogenic properties and its inhibition prevents the spread of cancer [89]. Many of the responses implicated in resistance to anti-angiogenic therapy may be mediated by HIF-1α activated genes [90]. The well-described inducers of EMT, Snail, Slug and Twist are themselves induced by hypoxia [91]. Hypoxia may also affect stem cells [92], and studies on this particular subpopulation of cells in tumors would be relevant to the metastatic process as cells surviving under hypoxic conditions become aggressive and pluripotent. Development of novel hypoxia-targeted therapies include bioreductive prodrugs, HIF-1 targeting, and genetic engineering of anaerobic bacteria [93].

Low extracellular pH is another consequence of the abnormal metabolism in the tumor and supportive factor for its progression. Products of anaerobic glycolysis - lactic acid and carbonic acid (produced by carbonic anhydrase from CO2 and H2O), are the known sources of H+ ions in tumors [94,95]. The imbalance between increased production of H+ ions and their reduced removal, lowers the extracellular pH in tumors. The mean pH profiles also decrease in tumors with increasing distance from nearest blood vessels. Low extracellular pH causes stress-induced alteration of gene expression, including the upregulation of VEGF and IL-8 in tumor cells in vitro [96]. Coordinated study of pH, pO2, and VEGF expression in vivo [97] indicated that in low pH or oxygenated regions, tissue pH, but not pO2, regulates VEGF promoter activity. Conversely, in hypoxic or neutral pH regions, tissue pO2 and not pH regulates VEGF expression [97]. Tissue pO2 and pH appear to regulate VEGF transcription in tumors independently. These data suggest that these key microenvironmental parameters in solid tumors regulate angiogenic factors in a complementary manner.

Another feature of the pathophysiology of the tumor microenvironment, is elevated interstitial fluid pressure (IFP) ranging from 10 to 100 mmHg [98,99] while IFP of normal tissue is around zero [100]. It is thought that the tumor vasculature is the driving force in increasing tumor IFP [101,102]. In contrast to normal vasculature which is characterized by dichotomous branching, tumor vasculature is unorganized and has trifurcations and branches with uneven diameters. Large inter-endothelial junctions, increased numbers of fenestrations, vesicles and vesico-vacuolar channels and a lack of normal basement membrane are often found in tumor vessels [103]. Due to ultrastructural alterations in the tumor vessel wall, vascular permeability in solid tumors is generally higher than that in various normal tissues [100]. Tumors also lack lymphatic vessels or the intratumoral vessels are non-functional [104,105] and as a result, excess fluid accumulates in the interstitium, extending the elastic ECM and elevating IFP. Using the model of IFP regulation Heldin et al. [106] showed that fibroblasts actively regulate the tension applied to the ECM through integrins which enable them to exert or modify tension on the collagen fibre network, thereby modulating the elasticity of the ECM in response to hyaluronan and proteoglycan expansion [106]. According to Oldberg et al. [107], inflammatory processes in carcinomas promote synthesis of collagen binding proteoglycan fibromodulin by stroma cells, leading to the formation of a dense and stiff collagen scaffold and a high IFP. Interstitial fluid pressure may have important clinical implications with regard to cancer therapy. Roh et al. [108] reported an inverse relationship between tumor IFP and tissue oxygenation and hypothesized that IFP may aid in predicting the efficacy of radiation therapy. Elevated tumor IFP can also act as a barrier to delivery of therapeutic agents, thereby reducing their efficacy. In this sense, multiple studies have demonstrated improved uptake of chemotherapeutic drugs following a reduction in tumor IFP [60,59,109,110].

Conclusion

Interactions during which the tumor creates a microenvironment favourable for proliferation, for the recruitment of new blood vessels, and for the stimulation of the production of proteases that can degrade adjacent tissues, increase the likelihood of tumor development and invasion. Growing evidence points towards a key role of the multiple cellular and noncellular components of the tumor microenvironment such as cancer associated fibroblasts, immune and endothelial cells as well as matrix topology and stiffness, interstitial fluid pressure, growth induced solid stress, hypoxia and extracellular pH. Full understanding of all the events driving the interaction of tumor cells with their environment is of
crucial importance in overcoming treatment resistance and in better patient outcome.

Competing interests
The authors declare that they have no competing interests.

Authors' contributions
GK conceived the idea, did literature search and drafted the manuscript; DS did literature search and contributed in drafting the manuscript; MK, NN and KB were involved in discussion and drafting the manuscript; JB supervised the project, made substantial contributions to the concept and design of manuscript, and drafted the manuscript. All authors read and approved the final manuscript.

Acknowledgements
This work was supported in part by grants NT13573 from the Czech Ministry of Health and NPU I LL03104 from the Czech Ministry of Education. DS was also supported by LF_2014_003.

Author details
1Laboratory of Molecular Pathology, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. 2Department of Pediatrics and Laboratory of Experimental Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. 3School of Cancer Sciences, University of Birmingham, Birmingham, UK.

Received: 8 November 2013 Accepted: 9 May 2014

References
1. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001, 411:375–379.
2. Kopecek O, Asari R, Niederle B, Kasner K. Desmoplastic stromal reaction in papillary thyroid microcarcinoma. Histopathology 2011, 58:919–924.
3. Dudley AC, Shih SC, Cliffe AR, Hida K, Christofori G. Attenuated p53 activation in tumour-associated stromal cells accompanies decreased sensitivity to etoposide and vincristine. Br J Cancer 2008, 99:118–125.
4. Barcellos-Hoff MH, Ravani SA. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Research 2000, 60:1254–1260.
5. Dranoff G. Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 2004, 4:11–22.
6. Mueller MM, Fusseneg NF. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 2004, 4:839–849.
7. Baerewyl V, Christofori G. The angiogenic switch in carcinogenesis. Semin Cancer Biol 2009, 19:239–337.
8. Chang HY, Sneddon JB, Alizadeh AA, Sood R, West RB, Montgomery K, Chi JT, van de Rijn M, Botstein D, Brown PO. Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol 2004, 2:e27.
9. Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer 2005, 5:392–401.
10. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, Richardson AL, Polya K, Tubo R, Weinberg RA. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449:557–563.
11. Mao Y, Keller ET, Garfield DH, Shen K, Wang J. Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev 2013, 32:303–315.
12. Ferrara N: VEGF as a therapeutic target in cancer. Oncology 2005, 69:Suppl 3:11–16.
13. Herrera M, Herrera A, Dominguez G, Silva J, Garcia V, Garcia JM, Gomez I, Soldevilla B, Munoz C, Provencio M, Campos-Martin Y, Garcia de Herreros A, Casal I, Bonilla F, Peris C. Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients. Cancer Sci 2013, 104:437–444.
14. Patocs A, Zhang L, Xu Y, Weber F, Caldes T, Mutter GL, Platzer P, Eng C. Breast-cancer stromal cells with TPM3 mutations and nodal metastases. N Engl J Med 2007, 357:2543–2551.
15. Baronzio G, Freitas I, Riwan HC. Tumor microenvironment and hemochromatological abnormalities. Semin Thromb Hemost 2003, 29:469–497.
16. Elfenbaa B, Weinberg RA: Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res 2001, 264:169–184.
17. Singer CF, Schwantrieder-Kaulich D, Fink-Retter A, Haas C, Hudekist G, Czerwenka K, Kubista E: Differential gene expression profile in breast cancer-derived stromal fibroblasts. Breast Cancer Res Treat 2008, 109:273–281.
18. Casey T, Bond J, Tighe S, Hunter T, Linton A, Patel O, Eneman J, Crocker A, White J, Testore J, Stanley M, Harlow S, Weaver D, Mott H, Plaut K. Molecular signatures suggest a major role for stromal cells in development of invasive breast cancer. Breast Cancer Res Treat 2009, 114:67–62.
19. Schulz WA, Burchardt M, Coronauer MV: Molecular biology of prostate cancer. Mol Hum Reprod 2003, 9:837–848.
20. Chaunu VP, Stylianopoulos T, Boucher Y, Jain RK: Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng 2011, 2:281–298.
21. Untergasser G, Gander R, Lulg C, Lepperdinger G, Plas E, Berger P. Profiling molecular targets of TGF-beta1 in prostate fibroblast-to-myofibroblast transdifferentiation. Mech Ageing Dev 2005, 126:53–69.
22. Rajski M, Zanetti-Dallenbach R, Vogel B, Herrmann R, Rochlitz C, Bues M: IGFl induces genes in stromal fibroblasts predict the clinical outcome of breast and lung cancer patients. BMC Med 2010, 8:1.
23. Kharaisiliv G, Cizkova M, Bouchalova K, Mgebirshvil G, Kolar Z, Bouchal J: Collagen triple helix repeat containing 1 protein, peristin and versican in primary and metastatic breast cancer: an immunohistochemical study. Pathol Oncol Res 2011, 17:675–682.
24. Sasaki H, Yu CY, Dai M, Tam C, Loda M, Auclair D, Chen LB, Elias A: Elevated serum peristin levels in patients with bone metastases from breast but not lung cancer. Breast Cancer Res Treat 2003, 77:245–252.
25. Schmidt-Hansen B, Omas D, Grigorian M, Ringelhofa J, Tulchinsky E, Lukhendin E, Ambartsumian N: Extracellular S100A4(mts1) stimulates invasive growth of mouse endothelial cells and modulates MMP-13 matrix metalloproteinase activity. Oncogene 2004, 23:5487–5495.
26. Ruiz C, Huang W, Heji ME, Lange K, Hamou MF, Fluri E, Oakley EJ, Chiquet-Ehrismann R, Gorod G: Growth promoting signaling by tenascin-C (corrected). Cancer Research 2004, 64:7377–7385.
27. Akin G, Sabo E, Dahi H, Vaidzis Z, Karvelishvil G, Yan G, Nessler O, Cohen T, Resnick M, Neerman M, Neufeld G: Lysyl oxidase-related protein-1 promotes tumor fibrosis and tumor progression in vivo. Cancer Research 2003, 63:1657–1666.
28. Hockel M, Vaupel P: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001, 93:266–276.
29. Oskarsson T, Massague J: Extracellular matrix players in metastatic niches. EMBO J 2012, 31:254–256.
30. Malanchi I, Santamaria-Martin A, Susanto S, Peng H, Lehr HA, Delayo JF, Huelken J: Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2012, 481:85–89.
31. Zeng YA, Nusse R: Wnt proteins are self-renewal factors for mammmary stem cells and promote their long-term expansion in culture. Cell Stem Cell 2010, 6:568–577.
32. Reya T, Clevers H: Wnt signalling in stem cells and cancer. Nature 2005, 434:843–850.
33. Barker N, Ridgway RA, van ES JH, de vatering M, Begthel H, van den Born M, Danenberg E, Clarke AR, Sansom OJ, Clevers H. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009, 457:508–611.
34. Kharaisiliv G, Simkova D, Makharobidze E, Tirttova K, Kolar Z, Bouchal J: Wnt signaling in prostate development and carcinogenesis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2011, 155:1–18.
35. Turashvili G, Bouchal J, Baumlforth K, Wei W, Dzieciatkova M, Ehrmann J, Klein J, Fridman E, Skarda J, Srovnal J, Hajduch M, Murray P, Kolar Z: Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer 2007, 7:55.
36. Turati A, Muameci D, Wang Y, Dumont B, Somja J, Bevilacqua G, De Pauw E, Delvienne P, Castronovo V: Identification of novel accessible proteins bearing diagnostic and therapeutic potential in human pancreatic ductal adenocarcinoma. J Proteome Res 2011, 10:3032–4313.
37. Chouaib S, Kieda C, Benlalham H, Norman MZ, Mami-Chouaib F, Ruegg C: Endothelial cells as key determinants of the tumor microenvironment: interaction with tumor cells, extracellular matrix and immune killer cells. Crit Rev Immunol 2010, 30:529–545.
40. Kurose K, Gilley K, Matsumoto S, Watson PH, Zhou XP, Eng C: Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet 2002, 32:355–357.

41. Shao R, Bao S, Bai X, Blanchette C, Anderson RM, Dang T, Ghazizky ML, Marks JR, Wang XF: Acquired expression of peroxisome proliferator by human breast cancers promotes tumor angiogenesis through up-regulation of vascular endothelial growth factor receptor 2 expression. Mol Cell Biol 2004, 24:3992–4003.

42. D’Adamo DR: Appraising the current role of chemotherapy for the treatment of sarcoma. Semin Oncol 2011, 38(suppl 3):519–529.

43. Sonnenberg M, van der Kuip H, Haubeis S, Fritz P, Schroth W, Friedel G, Simon W, Murdter TE, Audizy WE: Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast. BMC Cancer 2008, 8:364.

44. Li G, Satyamoorthy K, Herlyn M: Matrix mechanics.

45. Sonnenberg M, van der Kuip H, Haubeis S, Fritz P, Schroth W, Friedel G, Simon W, Murdter TE, Audizy WE: Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast. BMC Cancer 2008, 8:364.

46. Petrie RJ, Doyle AD, Yamada KM: Controlling matrix stiffness and topography for the study of tumor cell migration. Cell Adh Migr 2012, 6:274–279.

47. Kraning-Rush CM, Reinhart-King CA: Cell-Cell interactions promote survival and migration of melanoma cells. Cancer Res 2011, 71:4904–4915.

48. Petrie RJ, Doyle AD, Yamada KM: Controlling matrix stiffness and topography for the study of tumor cell migration. Cell Adh Migr 2012, 6:274–279.

49. Durand RE, Raleigh JA: How matrix properties control the self-assembly and treatment of sarcoma. Curr Opin Oncol 2009, 21:215–221.

50. Boghaert E, Gleghorn JP, Lee K, Gjorevski N, Radisky DC, Nelson CM: Matrix crosslinking forces tumor progression by enhancing integrin signaling.

51. Reinhart-King CA: Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139:891–906.

52. Solinas AR, Perazzolo MM, Sanchez LM, Lopez-Otin C: Matrix metalloproteinase activity in cancer: from new functions to improved inhibition strategies. Int J Biochem Cell Biol 2004, 36:411–429.

53. Brabek J, Mierke CT, Rosel D, Vesely P, Fabry B: The role of the tissue microenvironment in the regulation of cancer cell motility and invasion.

54. Knarre-Rush CM, Reinhart-King CA: Controlling matrix stiffness and topography for the study of tumor cell migration. Cell Adh Migr 2012, 6:274–279.

55. Stylianopoulos T, Martin JD, Chauhan VP, Liu H, Lacorre DA, Jain SR, Koizun SV, Stylianopoulos T, Mousa AS, Han X, Adstamrongkulkul P, Popovic Z, Huang P, Bawnudi MG, Boucher Y, Jain RK: Angiogenesis inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun 2013, 4:2516.

56. Honn KV, Tang DG: Adhesion molecules and tumor cell interaction with endothelium and subendothelial matrix. Cancer Metastasis Rev 1992, 11:353–375.

57. Olive KP, Jacobetz MA, Davidson CJ, Gopinathan A, McIntyre D, Honess D, Bhattacharyya SN, Chaturvedi TK, D’Ambrosio S, Cooney RV, Wang XF, Honn KV: Distinct epigenetic changes in the stromal cells of breast cancers. Nat Genet 2005, 37:899–905.

58. Castellsague X, Bosch FX, Munoz N: Environmental co-factors in HPV carcinogenesis. Virus Res 2002, 89:191–199.

59. Nelson WG, DeWeese TL, DeMarzo AM: The diet, prostate inflammation, and the development of prostate cancer. Cancer Metastasis Rev 2002, 21:6–16.

60. Lewis CE, Pollard JW: Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006, 66:605–612.

61. Inoue T, Pleith D, Venkov CD, Xu C, Nieslon EG: Antibodies against macrophages that overlap in specificity with fibroblasts. Kidney Int 2005, 67:2488–2493.

62. Goetz JC, Minuet S, Navarro-Leal I, Lazzano JJ, Samaniego R, Calvo E, Tello M, Oteo-Elezabat P, Tellez E, Achari A, Cerezo A, Klein-Szanto AJ, Garcia R, Keely PJ, Sanchez-Mateos P, Cukerman E, Del Pozo MA: Biomechanical remodelling of the microenvironment by stromal caveolin-1 favors tumor invasion and metastasis. Cell 2011, 146:148–163.

63. Fukumada D, Jain RK: Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J Cell Biochem 2007, 101:597–609.

64. Serensen GJ: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003, 3:712–721.

65. De Wever O, Nguyen QT, Van Hoorde L, Bracke M, Bruyneel E, Gespach C, Mareel M, Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-inflammatory signals to human colon cancer cells through RhoA and Rac. FASEB J 2004, 18:1016–1018.

66. Zunzmeeg A, Christofori G: Corrupt policemen: inflammatory cells promote tumor angiogenesis. Curr Opin Oncol 2009, 21:650–70.

67. Kobayashi Y: The role of chemokines in neutrophil biology. Front Biosci 2008, 13:2400–2407.

68. Lin CW, Shen SC, Ko CH, Lin HY, Chen YC: Reciprocal activation of macrophages and breast carcinoma cells by nitric oxide and colony-stimulating factor-1. Carcinogenesis 2010, 31:2039–2048.

69. Coussens LM, Werb Z: Inflammation and cancer. Nature 2002, 420:860–867.

70. Balkwill F: Cancer and the chemokine network. Nat Rev Cancer 2004, 4:540–550.

71. Egeblad M, Littlepage LE, Werb Z: The fibroblastic crosstalk in cancer progression. Cold Spring Harb Symp Quant Biol 2005, 70:383–388.

72. Li L, Neaves WB: Normal stem cells and cancer stem cells: the niche matters. Cancer Res 2006, 66:4553–4557.

73. Nieppert A, Piaemans M, Martini B, Delbono P, Berghmans T, Verbeek J, Latifee JJ, Mascaux C, Sillery JP: The role of microvesicle density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2002, 87:694–701.

74. Rausch M, Rajski M, Vogel-Durrer BM, Hermann R, Rochtitz C: Tumor-endothelial interaction links the CD44(+)CD24(−) phenotype with poor prognosis in early-stage breast cancer. Neoplasia 2009, 11:597–602.

75. Feldman CR, Rubinstein E, Nussinov R, Bedrosian I: High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer 2004, 4:420–427.

76. Ishiwata T, Matsuda Y, Naito Z: Nutrition in gastrointestinal and other cancers: effects on cells and tumor angiogenesis. World J Gastroenterol 2011, 17:409–418.

77. Teranishi N, Naito Z, Ishiwata T, Tanaka N, Furukawa K, Seya T, Shinjii S, Tajiri T: Identification of neovascularization using nestin in colorectal cancer. Int J Oncol 2007, 30:593–603.

78. Kolar Z, Ehrmann J Jr, Turashvili G, Bouchal J, Mrkovy J: A novel myoepithelial/progenitor cell marker in the breast? Vechos Arch 2007, 450:607–609.
Inhibition of PDGF receptor signaling in tumor stroma enhances cancer cell invasion. Cancer Res 2000, 60:2620–6204.

Oldberg A, Kalamajska S, Salnikov AV, Stuhr L, Morgelin M, Reed RC, Heldin NE, Rubin K. Collagen-binding proteoglycan fibromodulin can determine stroma matrix structure and fluid balance in experimental carcinoma. Proc Natl Acad Sci U S A 2007, 104:13966–13971.

Roh HD, Boucher Y, Kalnicki S, Buchbaum R, Bloomer WD, Jain RK. Intestinal hypertension in carcinoma of uterine cervix in patients: possible correlation with tumor oxygenation and radiation response. Cancer Res 1991, 51:6695–6698.

Vahovic G, Ponce AM, Rabbani Z, Salahuddin FK, Zgonjanin L, Spasojevic I, Vujaskovic Z, Dewhirst MW. Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. Br J Cancer 2007, 97:735–740.

Pieters K, Rubin K, Sjoblom T, Budinger E, Sjoquist M, Heldin CH, Ostman A. Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 2002, 62:5476–5484.

Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit